NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

January 8, 2024

Study Completion Date

January 22, 2024

Conditions

Mild Cognitive Impairment

Interventions

DRUG

Niagen®

250 mg capsules (4 capsules daily)

OTHER

Placebo

placebo

Trial Locations (1)

Neurovascular Aging Laboratory, Newark

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

University of Delaware

OTHER

NCT03482167 - NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter